Medincell Sustainability Profile
Medincell, a pioneering biopharmaceutical company headquartered in France, focuses on the development of innovative long-acting injectable therapies. Founded in 2000, the company has made significant strides in the industry, particularly in the fields of mental health and chronic diseases. Medincell's proprietary technology platform, which enables the sustained release of active pharmaceutical ingredients, sets it apart from competitors. With a strong presence in Europe and expanding operations globally, Medincell is committed to addressing unmet medical needs through its core products, including its lead candidate for the treatment of schizophrenia. The company has garnered recognition for its unique approach to drug delivery, positioning itself as a leader in the biopharmaceutical sector. Medincell continues to advance its mission of improving patient outcomes through innovative therapeutic solutions.
DitchCarbon Score
How does Medincell's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Medincell's score of 31 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Medincell's reported carbon emissions
In 2024, Medincell reported total carbon emissions of approximately 5,000,000 kg CO2e, with emissions distributed across various scopes. Specifically, Scope 1 emissions were about 776 kg CO2e, primarily from mobile combustion, while Scope 2 emissions totalled approximately 40,820 kg CO2e, all from purchased electricity. The most significant contributor to their carbon footprint was Scope 3 emissions, which amounted to around 4,500,000 kg CO2e. This included substantial figures from purchased goods and services (approximately 4,210,000 kg CO2e), capital goods (about 438,230 kg CO2e), and business travel (approximately 212,750 kg CO2e). In 2023, Medincell's emissions were lower, with total emissions of about 5,000,000 kg CO2e, including Scope 1 emissions of 0 kg CO2e and Scope 2 emissions of approximately 12,860 kg CO2e. Scope 3 emissions were again the largest portion, totalling around 4,800,000 kg CO2e. Medincell has not set specific reduction targets or initiatives as per the available data, and there are no climate pledges reported. The company’s emissions data is not cascaded from a parent organisation, indicating that it operates independently in its reporting and climate commitments. Overall, Medincell's emissions profile highlights a significant reliance on Scope 3 emissions, particularly from purchased goods and services, which presents an opportunity for future reduction initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | 000 |
| Scope 2 | 8,380 | 0,000 | 0,000 | 0,000 | 00,000 | 00,000 |
| Scope 3 | - | - | - | - | 0,000,000 | 0,000,000 |
How Carbon Intensive is Medincell's Industry?
How Carbon Intensive is Medincell's Location?
Medincell's Scope 3 Categories Breakdown
Medincell's Scope 3 emissions, which decreased by 12% last year and decreased by approximately 12% since 2023, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 74% of Scope 3 emissions.
Top Scope 3 Categories
Medincell's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Medincell has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
